[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"borderline-personality-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:borderline-personality-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,48,73,100,125,156,183,217,243,273,316,339,368,391,417,440,464,489,511,540,566,589,621,640,660],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100618920","conceptualizing-borderline-personality-disorder-as-a-relationship-use-disorder-100618920",false,"NCT07337889","Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder","TLUR","Inclusion Criteria:\n\n* General : aged 18-45\n* Specific :\n* Borderline personality disorder (BPD)assessed by SCID, without bipolar disorder\n* Bipolar disorder (assessed by SCID), without BPD (evaluated by SCID)\n* Healthy controls with no psychiatric disorders (screened by SCID).\n\nExclusion Criteria:\n\n* Psychotic disorders (evaluated by SCID)\n* lack of informed consent\n* Not affiliated with social security\n* Under judicial or administrative confinement or involuntary hospitalization\n* Protected by law (e.g., under guardianship)\n* Pregnancy or breastfeeding\n* Inability to understand, speak, or write in French\n* Inability to understand the study's purpose or methodology\n* Excluded from another study during the exclusion period\n* Participants who have received over €6000 in annual indemnities\n* For Bipolar Participants (without BPD) : Current moderate or severe depressive episode (BDI score \\> 18) or Current hypomanic\u002Fmanic episode (YMRS \\\u003C 12)",true,"ALL","18 Years","45 Years",{"count":22,"type":23},194,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to explore a novel conceptualization of Borderline Personality Disorder (BPD) as a \"Relationship Use Disorder.\" The research proposes that BPD shares key features with behavioral addictions, specifically addiction to interpersonal relationships. The study builds upon previous findings suggesting that individuals with BPD experience intense emotional dysregulation, including negative self-perception, shame, and a compulsive need for external validation. This addiction to relationships, much like substance use disorders, is thought to contribute significantly to the difficulties faced by these individuals, including interpersonal conflicts, self-destructive behaviors, and emotional instability.\n\nThe study seeks to demonstrate that the relational difficulties central to BPD meet the diagnostic criteria for addiction as defined by the DSM-5. It will also explore how these relational struggles are mediated by dysfunctional self-perception and whether they are linked to behaviors such as compulsive sexual behaviors (CSBD) or suicidal tendencies. Additionally, the research will investigate the relationship between addiction to relationships and neurobiological factors, including endorphin levels, in individuals with BPD compared to those with bipolar disorder and healthy controls. The hypothesis is that individuals with BPD will exhibit higher levels of relationship addiction, with this addiction being tied to their perception of self-worth and emotional experiences in relationships.\n\nThis innovative approach aims to refine the understanding of BPD, reduce stigma, and improve treatment strategies by providing scientific evidence supporting the conceptualization of BPD as a \"Relationship Use Disorder.\"",[29,30,31],"Borderline Personality Disorder","Borderline Personality Disorder (BPD)","Bipolar Disorder (BD)",[33,34],"borderline personality disorder","relationship-use disorder","RECRUITING","2026-06-18",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2026-06-01",{"date":43,"type":23},"2028-08-01",{"name":45,"class":46},"University Hospital, Montpellier","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100593056","phase-1-a-study-to-test-how-bi-3031185-is-tolerated-by-people-with-borderline-personality-disorder-or-attention-deficithyperactivity-disorder-100593056","NCT07001475","A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit\u002FHyperactivity Disorder","A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n* Male, female, and non-binary participants, 18 to 45 years of age, both inclusively, at the time of consent\n* Meet current diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) criteria as primary diagnosis as assessed by the mini international neuropsychiatric interview (MINI) at screening for borderline personality disorder (BPD) OR attention-deficit\u002Fhyperactivity disorder (ADHD). With full implementation of version 5.0 of this clinical trial protocol (CTP), only participants with a primary diagnosis of ADHD as assessed by the MINI will be included in the trial.\n* Willingness to abstain from alcohol for 24 h, and all other drugs of abuse including cannabis for 72 h prior to Visits 2 and 3 (Day -1). Willingness to abstain from alcohol and cannabis for 72 h after investigational medicinal product (IMP) administration, as well as from all other recreational drugs for the duration of the trial\n* Willingness to abstain from prescribed psychostimulants for 72 h prior to Visits 2 and 3 (Day -1) and 24 h following IMP administration Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, delusional disorder, autism spectrum disorder, or antisocial personality disorder as confirmed by the MINI\n* Any other psychiatric disorder that is not currently stable in symptoms and treatment\n* Any substance use disorder within 3 months prior to randomisation (excluding mild alcohol, cannabis, tobacco, and caffeine use disorders); or moderate to severe substance use disorder within the 6 months prior to randomisation (excluding tobacco and caffeine)\n* Positive drug screen. Participants with positive cannabis drug tests can be included if they do not meet criteria for moderate or severe cannabis use disorder and the investigator determines that use will not be an impediment to trial participation or accurate data collection\n* Concomitant use of psychotropic medication except for the ones below. All other psychotropic medications must be washed out at least 30 days or 5 Half-life time (t1\u002F2) (whichever is longer) before the start of Visit 2 (Day -1)\n\n  1. A single SSRI (selective serotonin re-uptake inhibitor) or SNRI (selective serotonin and norepinephrine re-uptake inhibitor) antidepressant that has been stable in dose and frequency for \\>3 months prior to randomisation\n  2. A single second-generation antipsychotic at a low dose that has been stable in dose and frequency for \\>3 months prior to randomisation (low dose = 1 thorazine dose equivalent or less, which translates to ≤2 mg\u002Fday for risperidone, 5 mg\u002Fday for olanzapine, 75 mg\u002Fday for quetiapine, 60 mg\u002Fday for ziprasidone, and 7.5 mg\u002Fday for aripiprazole)\n  3. A single sleep medication given as a nightly scheduled medication (not pro re nata) stable in agent and dose for \\>3 months prior to screening. Allowed sleep medications include: non-benzodiazepine Z sleep medications, antihistamines, melatonin, trazodone, and doxepin\n  4. Participants taking psychostimulant medication prescribed as per label for ADHD must stop medication 72 h prior to Visits 2 and 3 (Day -1) and may resume 24 h after receiving the medication dose on the test day (i.e. 5 days total off of prescribed psychostimulant for Visit 2 and 5 days off of prescribed psychostimulant for Visit 3)\n* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix\n* A positive result for any active hepatitis\n* Previous randomisation in this trial Further exclusion criteria apply.",{"count":56,"type":23},68,[58],"PHASE1","This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions.\n\nParticipants are put into 2 groups of equal size randomly, which means by chance. Group 1 takes a single dose of BI 3031185 and Group 2 takes placebo. After a 2-week break, Group 1 takes placebo and Group 2 takes a single dose of BI 3031185. Participants take BI 3031185 and placebo as tablets.\n\nParticipants are in the study for about 3 months. They visit the study site 6 times and have 3 phone or video call visits. For 2 of the visits, participants stay overnight at the study site for 2 nights. During all the visits, doctors check participants' health and take note of any unwanted effects.",[29,61],"Attention Deficit Hyperactivity Disorder","2026-06-12",{"date":64,"type":39},"2026-06-15",{"date":66,"type":39},"2025-08-12",{"date":68,"type":23},"2026-11-27",{"name":70,"class":71},"Boehringer Ingelheim","INDUSTRY",7,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100550414","phase-2-mindfulness-based-neurofeedback-to-augment-psychotherapy-for-adults-with-borderline-personality-disorder-100550414","NCT06446765","Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder","Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults With Borderline Personality Disorder (Aim 1)","MIND-BPD","Inclusion criteria:\n\n* age 18-60,\n* be able to provide written informed consent,\n* meet criteria for BPD on semi-structured clinical interview,\n* able to plan to keep any prescribed medications and psychotherapy constant during the study\n* fluent in English.\n\nExclusion criteria:\n\n* current DBT psychotherapy outside the study\n* lifetime primary psychotic disorder\n* manic episode in the last one year\n* developmental disorder (e.g. autism)\n* history of learning disorder\n* severe substance use disorder in the last 3 months\n* active suicidal ideation with intent or plan in the past 3 months\n* history of major medical or neurologic disorder\n* MRI contraindications, including pregnancy\n* poor performance on reading task (WRAT \\> 11 errors)\n* newly prescribed medications in the past 8 weeks\n* daytime sedating medications (e.g. benzodiazepines, opiates, sedating neuroleptics)\n* any scheduled daily benzodiazepines\n* change in psychotherapy type or frequency in the past 12 weeks.\n* At the discretion of the study PI\n\nEligibility will be determined by study personnel.","60 Years",{"count":83,"type":23},150,[85],"PHASE2","The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).",[29],[89,90],"fMRI neurofeedback","mindfulness","2026-06-08",{"date":93,"type":39},"2026-06-09",{"date":95,"type":39},"2025-03-13",{"date":97,"type":23},"2026-10-30",{"name":99,"class":46},"Yale University",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100500797","triage-survey-for-psychiatry-research-eligibility-100500797","NCT05800925","Triage Survey for Psychiatry Research Eligibility","TRIAGE-Psych","Inclusion Criteria:\n\n* Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.\n* Participant is at least 18 years old.\n\nExclusion Criteria:\n\n* Participant is pregnant, breast-feeding, or planning to become pregnant.\n* History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.\n* Participant represents an acute suicidal risk, as defined as a \"yes\" response to ideation on C-SSRS questions 4 or 5, or answer \"yes\" to behavior questions within 90 days of screening.\n* Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant.\n* Any condition that in the investigator's opinion makes a participant unsuitable for the study.\n* Currently employed by Adams Clinical or a first-degree relative of an employee.",{"count":108,"type":23},20000,"OBSERVATIONAL","TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.",[112,29,113],"Major Depressive Disorder","Generalized Anxiety Disorder","2026-05-18",{"date":116,"type":39},"2026-05-20",{"date":118,"type":39},"2021-12-21",{"date":120,"type":23},"2027-12-31",{"name":122,"class":123},"Adams Clinical","NETWORK",6,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":24,"phases":133,"briefSummary":134,"conditions":135,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":47},"100489298","a-precision-medicine-approach-to-target-engagement-for-emotion-regulation-100489298","NCT05651295","A Precision Medicine Approach to Target Engagement for Emotion Regulation","Inclusion Criteria:\n\n* Elevated emotion dysregulation\n\nExclusion Criteria:\n\n* Lack of proficiency in English\n* No access to smartphone\n* Conditions requiring greater than outpatient care",{"count":132,"type":23},390,[26],"The proposed study is designed to first test whether teaching people personalized or standardized emotion regulation skills leads to greater decreases in daily negative emotion intensity. Second, using data from an initial sample, the investigators will prospectively assign an independent sample of participants to receive their predicted optimal or non-optimal skills to determine if it is feasible and efficacious to match participants to the most appropriate training condition. Results of these studies may identify the mechanisms by which emotion regulation interventions impact emotional functioning and allow for the development of personalized, evidence-based, and scalable emotion regulation interventions.",[136,137,138,29,139,140,141],"Emotional Regulation","Depression","Anxiety","Obsessive-Compulsive Disorder","Posttraumatic Stress Disorder","Eating Disorders",[143,144,145,146],"cognitive-behavior therapy","mechanism","ecological momentary assessment","personalization","2026-05-07",{"date":149,"type":39},"2026-05-11",{"date":151,"type":39},"2023-09-29",{"date":153,"type":23},"2026-12-31",{"name":155,"class":46},"Matthew Southward, PhD",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":24,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":47},"100559387","pegasus---improving-treatment-for-patients-with-emotionally-unstable-personality-disorder-100559387","NCT06563466","PEGASUS - Improving Treatment for Patients With Emotionally Unstable Personality Disorder","Participating Patients\n\nInclusion Criteria:\n\n* Must be able to give an informed written consent.\n* Must be newly accepted in the pre-planned BPD treatment packages.\n* ≥18 years of age.\n* Agreeing to involvement of one or two informal caregivers, families, or close friends (\"Relatives\").\n* Capable of reading and understanding Danish.\n\nExclusion Criteria:\n\n* None\\*\n\n  * Note that to get accepted into a treatment package for BPD, patients must not fulfill the criteria for a F20 diagnosis or the criteria for alcohol or substance abuse or harmful use.\n\nParticipating Relatives:\n\nInclusion Criteria:\n\n* Must be able to give an informed written consent.\n* ≥18 years of age.\n* Capable of reading and understanding Danish.\n\nExclusion criteria: None",{"count":163,"type":23},100,[26],"The purpose of the PEGASUS study is to conduct a pilot trial to test the feasibility and acceptability of the PEGASUS intervention, adding a case manager and family-based interventions meetings to the existing psychiatric integrated care-models known as \"Treatment Packages\" in Denmark. We will conduct a randomized, assessor-blinded parallel-groups superiority clinical trial, testing the PEGASUS intervention for emotionally unstable personality disorder \"EUPD\", borderline type (borderline personality disorder) compared to \"Treatment as Usual\" before moving on to testing in a full-scale trial. Participants will be assessed at baseline and 9 month post baseline at study conclusion",[29,167],"Relatives",[29,167,169,170,171,172,173],"Group psychotherapy","Case management","Psychoeducation","Family","Caregiver","2026-04-22",{"date":176,"type":39},"2026-04-28",{"date":178,"type":39},"2024-09-01",{"date":180,"type":23},"2029-08-31",{"name":182,"class":46},"University Hospital Bispebjerg and Frederiksberg",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100632094","long-term-follow-up-of-mentalization-based-treatment-exploring-variability-in-outcomes-long-term-value-and-experiences-10-year-after-receiving-mbt-day-hospital-or-mbt-intensive-outpatient-100632094","NCT07509216","Long Term Follow-up of Mentalization-Based Treatment: Exploring Variability in Outcomes, Long-term Value and Experiences 10+ Year After Receiving MBT Day Hospital or MBT Intensive Outpatient","MBT-EVOLVE: Mentalization-Based Treatment: Exploring Variability in Outcomes, Long-term Value and Experiences: A 10+ Year Follow-up of Two Types of MBT for BPD - Quantitative and Qualitative Perspectives on Long-term Functioning","MBT-EVOLVE","Inclusion Criteria:\n\n* Participation in the original randomized controlled trial of mentalization-based treatment (MBT-DH versus MBT-IOP)\n* Did not decline to be contacted for future research\n* Able to provide informed consent at the time of the long-term follow-up assessment\n\n(No separate exclusion criteria are specified, as exclusion follows directly from these inclusion criteria.)",{"count":192,"type":23},113,"This study is a long-term follow-up study of a previous multicenter randomized controlled trial, in which n=114 participants were included. This RCT compared the effectiveness of two intensities of mentalisation-based treatment (MBT) for individuals with borderline personality disorder (BPD).\n\nThe goal of this study is to learn how people who received MBT in the past for BPD are doing more than 10 years later. MBT is a type of psychotherapy that helps people understand and manage their thoughts and feelings, and supports improvements in identity and relationships, with the aim of improving daily life functioning.\n\nThe main questions this study aims to answer are:\n\n1. How are people who received MBT in the past functioning more than 10 years later, and how is their use of mental health care and associated costs at this point in their lives?\n2. Do long-term outcomes differ between people who received day-hospital MBT and people who received intensive outpatient MBT, and are these outcomes influenced by how much time has passed since treatment ended or by clinical characteristics from the past, such as symptom severity, trauma history, or level of mentalizing?\n3. How do people who received MBT experience its impact on their symptoms, daily life, and relationships both during treatment and in the years afterward, including the impact of treatment intensity?\n\nParticipants will:\n\n* Fill in online questionnaires about symptoms, relationships, health, and daily functioning (about 60 minutes).\n* Take part in a short interview to check whether BPD symptoms are still present (about 20 minutes).\n* A smaller group will be invited for a longer semi-structured qualitative interview (about 60 minutes) to talk about their personal experiences with MBT and what has impacted their life after treatment.\n\nThere are no new treatments in this study. All participants completed MBT many years ago. Participation happens online or in person based on personal preference.",[29],[196,197,198,33,199,200,201,202,203,204,205],"mentalisation-based treatment","health care utilization","long-term follow-up","psychosocial functioning","recovery","patient-reported outcomes","patient experiences","mixed-methods","qualitative research","health care costs","NOT_YET_RECRUITING","2026-04-03",{"date":209,"type":39},"2026-04-08",{"date":211,"type":23},"2026-04-02",{"date":213,"type":23},"2027-06",{"name":215,"class":46},"De Viersprong",2,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100551349","phase-2-testing-interventions-for-borderline-personality-disorder-100551349","NCT06458933","Testing Interventions for Borderline Personality Disorder.","A Randomized Controlled Trial Testing Sage: A Couple Intervention for Borderline Personality Disorder","INCLUSION CRITERIA\n\n1. Participant with borderline personality disorder (BPD) meets full diagnostic criteria for BPD (i.e., five or more BPD diagnostic criteria per the Diagnostic and Statistical Manual of Mental Disorders-5-TR)\n2. Both members are at least 19-years-old\n3. Both members consent to study participation\n4. Both members consent to a member of the research team contacting one of their provided emergency contacts if there are imminent safety concerns.\n5. Both members consent to having assessment interviews and treatment sessions audio- and video-recorded\n6. Both members members reside in Ontario (with no plan to leave the province during the course of the study)\n7. Both members members are fluent in English\n8. Both members are willing to receive emails about the study\n9. Both members have regular internet access from a private location for completion of study appointments\n\nEXCLUSION:\n\n1. Severe intimate partner violence in their relationship in the past year (Endorsement of severe intimate partner violence items on Conflict Tactics Scale-2)\n2. DSM-5 criteria A and B of schizophrenia, not better accounted for by BPD\n3. Hospitalization in the past year for mania, or mania in the past three months\n4. A substance\u002Falcohol use disorder that is likely to require medical intervention (e.g., detoxification) to reduce use\n5. A medical condition that is likely to require hospitalization within the next year\n6. Scaled score below 70 on the Test of Premorbid Functioning, suggesting impaired intelligence and\u002For probable traumatic brain injury\n7. Either participant in the dyad is not able to show proof of identification upon request at any point throughout the study or is not able to provide an accurate phone number or address upon request.\n8. The individual with BPD is currently receiving an empirically-supported BPD treatment and is unwilling to pause the therapy for the duration of the active treatment phase","19 Years",{"count":226,"type":23},304,[85],"Borderline personality disorder (BPD) is a life-threatening, costly public health crisis affecting \\~1-3% of North Americans, with 10% dying by suicide and annual healthcare costs of \\~$63k (Canadian Dollars)\u002Fpatient. Further, people with BPD's intimate relationships are highly disrupted, and their partners report elevated mental health problems but little access to treatment. Existing BPD treatments are resource-heavy, inaccessible, and 47% of people with BPD do not respond to them. These treatments also neglect relationship problems and intimate partner's mental health concerns, even though they are thought to play a key role in BPD maintenance. BPD interventions may produce stronger, quicker, and more durable outcomes if they incorporated partners to target both the emotional and relationship core of BPD. Moreover, incorporating partners into interventions may improve relationship outcomes and partner mental health without added resource investments.\n\nAccordingly, members of our team developed Sage. Named after a plant that thrives in relationship with its ecosystem, Sage is a brief, 12-session conjoint intervention for people with BPD and their intimate partners that targets BPD, relationship conflict, and partner mental health. Our recent uncontrolled trial provides preliminary support for its efficacy.\n\nAs a next step in testing Sage, it is critical to utilize a Randomized Controlled Trial (RCT) design to identify if Sage is more efficacious than standard care that these couples typically receive; supportive individual psychotherapy (SIP) for people with BPD and their partners. The investigators propose to conduct the first RCT of Sage for couples wherein one member has BPD. The study will examine if Sage is more efficacious than SIP in improving BPD symptoms (primary outcome), as well as relationship conflict and partner mental health (secondary outcomes), as well as a range of other outcomes, from pre- to post-intervention, and post-intervention to follow-up. It will also investigate factors that influence treatment response, BPD severity, and related problems.\n\nUp to 152 couples wherein one member has BPD will be randomized to receive Sage or SIP. Gold-standard measures of primary, secondary, and exploratory outcomes will be administered at baseline, mid-intervention, post-intervention, and a one-month, three- month, and six-month follow-up.",[29],[29,231,232,233],"Relationship dysfunction","Couple therapy","Emotion dysregulation","2026-03-26",{"date":236,"type":39},"2026-04-01",{"date":238,"type":39},"2025-09-01",{"date":240,"type":23},"2030-03-30",{"name":242,"class":46},"York University",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":47},"100629563","pilot-study-on-auricular-acupuncture-in-hospitalized-adults-with-borderline-personality-disorder-100629563","NCT07476300","Pilot Study on Auricular Acupuncture in Hospitalized Adults With Borderline Personality Disorder","Feasibility and Preliminary Effectiveness of a Nurse-led Auricular Acupuncture Intervention as a Complementary Therapy to Usual Treatments: A Pilot Study in Adults Hospitalized in Psychiatric Units With Borderline Personality Disorder","ACUPSY","Inclusion criteria\n\n* Aged 18 years or older\n* Currently hospitalized in a psychiatric unit at the Prangins site of Lausanne University Hospital (CHUV)\n* Diagnosed with borderline personality disorder, as documented in the medical record\n* Able to speak and understand French\n* Able to communicate verbally\n* Clinically stable enough to participate, as determined by the healthcare team\n* Able to understand the study information and provide written informed consent\n\nExclusion criteria\n\n* Presence of severe clinical instability, such as: marked agitation, high risk of suicide, risk of harm to others\n* Inability to provide informed consent (for example, due to impaired judgment or legal protective measures)\n* Currently hospitalized in a seclusion or isolation room\n* Expected discharge from hospital before completion of the five acupuncture sessions\n* Current treatment with anticoagulant (blood-thinning) medications\n* Current treatment with immunosuppressive medications\n* Currently receiving acupuncture treatment for any reason\n* Received acupuncture within the past three months for anxiety, emotional regulation, relaxation, or sleep problems\n* Participation in intensive behavioral therapy programs outside usual care that target similar outcomes\n* Presence of skin lesions, irritation, or infection on the ears\n* Severe fear of needles\n* Inability to remain still during acupuncture sessions",{"count":252,"type":23},15,[26],"The goal of this pilot study is to evaluate the feasibility and preliminary effectiveness of a brief auricular acupuncture program delivered by mental health nurses as a complementary therapy for adults hospitalized with borderline personality disorder (BPD). The main questions it aims to answer are:\n\n* Is participation in the five-session auricular acupuncture program feasible (in terms of attendance) for hospitalized adults with borderline personality disorder?\n* Does the auricular acupuncture intervention show potential benefits on emotional regulation, anxiety, sleep quality, and overall clinical status?\n\n  15 hospitalized adults with BPD will receive 5 individual ear acupuncture sessions, over a 9-day period, based on the National Acupuncture Detoxification Association (N.A.D.A.) protocol in addition to treatment as usual. Participants will complete brief questionnaires at several time points. The findings will inform the feasibility of the study procedures and guide the development of a future larger-scale clinical trial.",[29],[29,257,258,259,260,261,262,263],"Acupuncture","Complementary and Alternative Medicine","Psychiatric patients","Hospitalized patients","Feasibility Study","Pilot study","Mental Health Nursing","2026-03-11",{"date":266,"type":39},"2026-03-17",{"date":268,"type":23},"2026-04-15",{"date":270,"type":23},"2026-09",{"name":272,"class":46},"Jenny Gentizon",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":24,"phases":283,"briefSummary":284,"conditions":285,"keywords":298,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":47},"100493968","neurostimulation-versus-therapy-for-problems-with-emotions-100493968","NCT05712057","Neurostimulation Versus Therapy for Problems With Emotions","Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis","Inclusion Criteria:\n\n* age 18 to 55\n* elevated overall score on Difficulties with Emotion Regulation Scale (DERS total score \\>=90)\n* has been in the same type of psychotherapy (including none) for the last 4 weeks\u002F1mo (\\*except for current CBT) and is willing to stay on the same regimen throughout the study.\n* low self-reported use of cognitive restructuring (ERQ restructuring subscale average score \\\u003C 4.7)\n* meets criteria for at least one mood (including Bipolar II w\u002Fo current hypomania), anxiety, stressor, OCD, Impulse Control, ADHD, or eating DSM-5 disorder (except exclusionary diagnoses such as severe anorexia). Note: Both current or partial remission of the disorder will be ok for inclusion into the study.\n* verbal agreement to maintain dose of prescribed psychotropic medication (if any) constant throughout the study, provided they are stable on it for the past 4 weeks (except exclusion medication and except if there is a medical emergency requiring changes in medication).\n* Naïve to rTMS\n\nExclusion Criteria:\n\n* current hypomania (Note: Bipolar II w\u002Fo current hypomanic episode is ok for inclusion)\n* meets diagnostic criteria for current or history of psychotic disorder, or psychotic features,\n* meets diagnostic criteria for Bipolar I disorder\n* meets diagnostic criteria on SCID5 for current alcohol or substance use disorder (moderate and high severity) or meets past history of severe alcohol use disorder\n* unable to read, blind, or deaf, or unwilling to give consent\n* non-English speaker,\n* verbal IQ \\\u003C 90 on the North American Adult Reading Test (NART).\n* current uncontrolled anorexia or other condition requiring hospitalization\n* high risk for suicide defined as either having attempted suicide in past 6 months or reporting current suicidal ideation that includes a method, plan, or intent to die\n* current serious medical illness, including current severe migraine headaches\n* started\u002Fchanged psychotropic medications in the prior 4 weeks, or plans to change medication during the study\n* history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesions that are contraindications for TMS, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator), have left elbow\u002Fhand\u002Fwrist tendonitis\n* conditions associated with increased intracranial pressure, space occupying brain lesion (considered significant and unsafe for TMS by the study MD), transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis\n* Wellbutrin \\>300mg per day or on daily stimulant\u002FADHD medications above the recommended FDA daily recommendations\n* use of investigational drug or devices within 4 weeks of screening\n* cochlear implants\n* Pregnancy\n* metal in body that would exclude them from the MRI scan; severe claustrophobia\n* is a prisoner or in police custody at time of screening, or has pending court case jeopardizing the participation in the study\n* has had TMS in their lifetime\n* has had CBT in the past 4 weeks or plans to start therapy during the study\n* weighs over 300 pounds (could not fit in MRI scanner)","55 Years",{"count":282,"type":23},240,[26],"The primary goal of this clinical trial is to evaluate the unique neural and behavioral effects of a one-session training combining emotion regulation skills training, with excitatory repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC). The secondary aim is to identify key changes in the emotion regulation neural network following the combined intervention versus each of the components alone. The third aim is to explore personalized biomarkers for response to emotion regulation training.\n\nParticipants will undergo brain imaging while engaging in an emotional regulation task. Participants will be randomly assigned to learn one of two emotion regulation skills. Participants will be reminded of recent stressors and will undergo different types of neurostimulation, targeted using fMRI (functional MRI) results. Participants who may practice their emotion regulation skills during neurostimulation in a one-time session. Following this training, participants will undergo another fMRI and an exit interview to assess for immediate neural and behavioral changes. Measures of emotion regulation will be assessed at a one week and a one month follow up visit.",[286,287,288,289,290,291,141,292,293,294,295,296,139,297,29],"Emotion Regulation","Mood Disorders","Stress Disorder","Anxiety Disorders","OCD","Impulse Control Disorder","Emotional Dysfunction","Emotional Instability","Emotional Distress","Emotional Maladjustment","Emotional Impulsivity","Emotion Dysregulation",[297,299,300,301,302,303,304,305,306],"Distress Intolerance","Neuromodulation","Neurostimulation","TMS","cognitive restructuring","regulation skills","neuroimaging","Emotion regulation","2026-03-02",{"date":309,"type":39},"2026-03-04",{"date":311,"type":39},"2023-05-15",{"date":313,"type":23},"2027-12-01",{"name":315,"class":46},"Duke University",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":47},"100554024","effectiveness-of-emdr-in-borderline-personality-disorder-100554024","NCT06493708","Effectiveness of EMDR in Borderline Personality Disorder","Effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) Applied to Borderline Personality Disorder: an Interventional Prospective Case Control Study in a Real-world Care Setting","EMBODIER","Inclusion Criteria:\n\n* Patients must be over 18 years old\n* A current diagnosis of PBD according to the DSM-5 was confirmed using the SCID-5-CV and SCID-5-PD diagnostic scale\n\nExclusion Criteria:\n\n* Suicidal ideation in the last 3 months (suicidal thoughts active intentionally but without specific planning or suicidal thoughts active with planning and intentionality)\n* Intellectual disability\n* Any active disturbance from use of substances or alcohol\n* Any other diagnosis of Axis I, except for Depressive Disorders, Anxious Spectrum Disorders, Obsessive-Compulsive Disorder.","65 Years",{"count":326,"type":23},56,[26],"Borderline personality disorder (BPD) is a severe mental disorder characterized by four major symptomatological domains: interpersonal instability, perceptive and identity disorders, emotional and behavioural dysregulation. Considering a multifactorial etiological model, it has been suggested that the interaction between behavioral, environmental and genetic factors may promote the development of BPD. Early life stress events (ELS) in childhood and adolescence are highly prevalent in this population and constitute an environmental risk factor for the development of BPD. This correlates with the fact that Post-traumatic Stress Disorder (PTSD) is frequently comorbid in BPD leading to more severe symptoms and worse psychosocial functioning. At the therapeutic level, the treatment of BPD is an open challenge as psychotherapeutic interventions are of limited effectiveness and characterized by high drop-out rates. Eye Movement Desensitization and Reprocessing (EMDR) is the gold standard for treating PTSD. However, scientific evidence on the application of EMDR in patients with BPD is limited. This study aims to assess the feasibility and effectiveness of an EMDR protocol on the nuclear symptomatology of BPD (emotional and behavioral dysregulation) in a group of DBP patients with\u002Fwithout PTSD comorbidity, through a systematic assessment of the peculiar dimensions of the disorder. The basic hypothesis is that EMDR, through a short-term intervention, can act both on the traumatic PTSD-like experiences reported by patients and on the clinical manifestations peculiar to DBP, in particular by improving the emotional regulation capacity of patients with BPD.",[29],"2026-02-23",{"date":332,"type":39},"2026-02-25",{"date":334,"type":39},"2024-10-01",{"date":336,"type":23},"2026-10-01",{"name":338,"class":46},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":124},"100564254","phase-1-brain-signal-training-to-enhance-affect-down-regulation-100564254","NCT06626789","Brain Signal Training to Enhance Affect Down-regulation","A Multi-center, Patient-blinded and Investigator-blinded, Randomized, Parallel-group, Superiority Study to Compare the Efficacy of Four Sessions of Amygdala fMRI-BOLD Neurofeedback With Yoked Sham-control Neurofeedback in the Treatment of Dysregulated Affect in Borderline Personality Disorder","BrainSTEADy","Stage 1: 82 patients, stage 2: 82 patients Inclusion Criteria\n\n1. 18-65 years\n2. Diagnosis of Borderline Personality Disorder\n3. Insufficient response to ≥2 therapies.\n4. Sufficient German language skills to give informed consent to the study, to understand questions posed by used instruments, and capable of completing the fMRI tasks\n5. Ability of subject to understand character and individual consequences of clinical investigation\n6. Written informed consent (must be available before enrollment in the clinical investigation)\n7. For women of childbearing potential (WOCBP) adequate contraception.\n\nExclusion Criteria\n\n1. Treatment with benzodiazepines within 7 days prior the initial screening\n2. Current alcohol or substance dependence\n3. Meeting the diagnostic criteria for a psychotic disorder or schizophrenia (life-time), as determined by clinical interview at initial screening\n4. Current or history of significant neurological condition (such as stroke, traumatic brain injury, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack)\n5. Significant visual impairment that might interfere with the performance of the behavioural tasks or fMRI tasks\n6. Change of treatment (psychopharmacologic, psychological) 2 weeks prior to or during the study participation\n7. Treatment with any neurofeedback three months prior to or during the study participation.\n8. Unable or unwilling to comply with study procedures, including study prohibitions and restrictions\n9. History of claustrophobia or inability to tolerate scanner environment\n10. Fulfilling any of the MRI contraindications on the standard site radiography screening questionnaire (e.g. history of surgery involving metal implants)\n11. Clinically relevant structural brain abnormality as determined by prior MRI scan\n12. Planned medical treatment within the study period that might interfere with the study procedures\n13. Participants deemed to be at significant risk of serious violence or suicide\n14. BMI of 16.5 or lower\n15. Participation in other clinical trials or observation period of competing trials, respectively\n16. Previous participation in this trial\n17. Pregnancy and lactation\n18. Held in an institution by legal or official order\n19. Legally incapacitated.",{"count":348,"type":23},164,[58,85],"Individuals with Borderline Personality Disorder (BPD) experience intensive, instable negative emotions. Hyperactivity of the amygdala is assumed to drive exaggerated emotional responses in BPD. Neurofeedback is an endogenous neuromodulation method to address the imbalance of neural circuits. Downregulation of amygdala hyperactivation with neurofeedback may ameliorate dysregulated emotions in BPD. The BrainSTEADy trial is designed to determine whether amygdala-fMRI-BOLD neurofeedback has a specific effect on affect instability in BPD beyond nonspecific benefit.",[29],[353,354,355,356,357,358],"Neurofeedback","fMRI","Neuroimaging","Amygdala","Affect instability","Emotion","2026-01-30",{"date":361,"type":39},"2026-02-03",{"date":363,"type":39},"2025-04-23",{"date":365,"type":23},"2028-06",{"name":367,"class":46},"Central Institute of Mental Health, Mannheim",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":390,"locationsCount":47},"100568575","phase-2-mdma-in-borderline-personality-disorder-100568575","NCT06683014","MDMA in Borderline Personality Disorder","The Effects of MDMA (3,4-methylenedioxymethamphetamine) in Social Cognition in Borderline Personality Disorder","MDMA in BPD","Inclusion Criteria:\n\n* Adults between the ages of 18-60 years\n* Body weight between 110 and 210 pounds. Minimum body mass index (BMI) 16.5.\n* Able to swallow pills.\n* Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable and must sign release of information for this contact person.\n* People of childbearing potential must agree to utilize a highly effective method of birth control (including the following, in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) guidelines: combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation, including oral, intravaginal, and transdermal administrations; estrogen-only hormonal contraception associated with inhibition of ovulation, including oral, injectable, and implantable forms; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; abstinence from sexual activity with biological males) and for one month prior to dosing and for the duration of the two week follow-up period.\n* Able to provide written informed consent according to Yale IRB guidelines.\n* Able to read and write English proficiently.\n* Diagnosis of BPD, as determined by the Diagnostic Interview for Personality Disorders BPD questions (DIPD), including endorsement of the criteria for abandonment fears and for stormy relationships.\n* No exposure to MDMA in the last 6 months, and no more than 10 lifetime uses of ecstasy.\n* Agree not to drive a motor vehicle for 24 hours after the treatment day. Agree to identify a support person to accompany them home after the medication day.\n* Are willing to remain overnight at the study site after each experimental session until the next morning if recommended by the study physician\n* Currently not taking contraindicated medications (antidepressants, antipsychotics, mood stabilizers, stimulants).\n* Medications not on the contraindicated list must be reviewed and approved by the study PI\n* For people in mental health care, signs releases for the study investigators to communicate with their mental healthcare provider and medical doctor(s) about their medical and mental health history and their mental and medical status during the study. When contacted, the mental healthcare provider confirms the ongoing treatment relationship.\n* For people not in mental health care acknowledges receipt of local resources for mental healthcare.\n* For all participants, acknowledges receipt of local emergency resources\n\nExclusion Criteria:\n\n* History of bipolar disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the Structured Clinical Interview for DSM5 (SCID-5) and\u002For clinician assessment.\n* Lifetime diagnosis of autism.\n* Serious suicide risk in the past 6 months, as assessed by Columbia Suicide Severity Rating Scale (CSSRS) type 4 or 5 ideation, or suicidal behavior (CSSRS item) or preparatory acts (CSSRS item).\n* Any current substance use disorder (in the last 1 month) per SCID interview for alcohol or non-alcohol substances; or a positive pre-study (screening) urine drug screen.\n* Any severe substance use disorder during the last 6 months.\n* Any significant history of serious medical or neurological illness (including history of stroke, myocardial infarction, heart failure, cardiac arrhythmia, diabetes, family history of long-QT syndrome, etc.)\n* Any signs of major medical or neurological illness on examination, ECG screening, or laboratory tests. For QTc, we would exclude for QTcf \\>450. For liver function tests (AST, ALT), we will exclude for values more than 2.5 times the upper limit of normal range for our laboratory. For kidney function, we would exclude for eGFR \\\u003C 90 (n.b. our laboratory does use the contemporary non-race based formula for eGFR). Clinically significant electrolyte imbalances (sodium, potassium values out of range) will also be exclusionary (clinical significance to be determined by study MD review). A participant with a clinical abnormality may be included only if the study physician considers the abnormality will not introduce additional risk factors and will not interfere with the study procedure.\n* History of valvulopathy or pulmonary hypertension (due to evidence of 5HT2B receptor agonism by MDMA)\n* History of uncontrolled hypertension with baseline blood pressure above 130 mmHg (systolic) and over 90 mmHg (diastolic). Any history of syncope and\u002For study baseline blood pressure below 90 mmHg (systolic).\n* History of tachycardia with baseline heart rate above 90 beats per minute.\n* Current pregnancy or breastfeeding as assessed by patient report or by urine pregnancy test.\n* Taking any contraindicated medications: antidepressants, mood stabilizers, antipsychotics, stimulants. No patient will be encouraged to discontinue medications for the study. We will allow people to participate who stopped contraindicated medications at least five half-lives before baseline assessments.\n* Hypersensitivity to non-MDMA ingredients of the investigational medicine product (IMP), namely mannitol, magnesium stearate, and hydroxypropylmethylcellulose.\n* Herbal and dietary supplements will be reviewed on a case-by-case basis by the sponsor-PI for decision about safety.",{"count":377,"type":23},10,[85],"The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.",[29],[382,383],"3,4-methylenedioxymethamphetamine","social cognition","2026-01-21",{"date":386,"type":39},"2026-01-22",{"date":388,"type":39},"2025-09-05",{"date":270,"type":23},{"name":99,"class":46},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":280,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":47},"100575480","cognitive-reappraisal-training-for-borderline-personality-bpd-100575480","NCT06772831","Cognitive Reappraisal Training for Borderline Personality (BPD)","Cognitive Reappraisal Training Targeting Emotion Circuits As a Therapeutic Intervention in Borderline Patients","Inclusion Criteria:\n\n* Medically healthy men and women with Borderline Personality Disorder who are mentally competent and give informed voluntary written consent.\n* Participants will be between the ages of 18 and 55.\n* Within these requirements, the inclusion and exclusion criteria do not reflect participation based on gender or racial\u002Fethnic group. The targeted\u002Fplanned enrollment is a reflection of previous recruitment of female and ethnic minorities in other studies conducted by the PI and their colleagues and includes representations of both genders and all minorities.\n* Participants with comorbid avoidant personality disorder will be included.\n* Participants who meet criteria for PTSD will be included as long as they are not actively experiencing symptoms.\n\nExclusion Criteria:\n\n* Participants will not meet criteria for Schizotypal Personality Disorder.\n* Participants currently meeting criteria for Major Depressive Disorder will be excluded.\n* BPD participants will not meet DSM-5 criteria for present PTSD, bipolar I disorder, schizophrenia, schizoaffective disorder, substance use disorder within the past 6 months, organic mental syndromes, head trauma, schizotypal personality disorder, avoidant personality disorder, CNS neurological disease, or seizure disorder. Participants meeting criteria for a non-IV substance use disorder more than 6 months prior to enrollment will not be excluded. This study allows patients who are currently taking psychotropic medications or are in psychotherapy, so long as there has been no change in medication or psychotherapy over the preceding two months.\n* Participants currently meeting criteria for major depressive disorder.\n* Participants meeting criteria for substance use disorder within the last 6 months or of an IV-substance use disorder at any time.\n* Participants may not have a pacemaker, surgical clips, any metallic implants, or shrapnel fragments that would contraindicate MRI scanning.\n* Pregnant women.",{"count":399,"type":23},130,[26],"Previous work by the group convinced the researchers to pursue development of focused cognitive reappraisal training as a novel approach to treatment of BPD, either as stand-alone treatment or in concert with evidence-based treatments of BPD. The present proposal aims to refine and test a proposed clinical intervention for BPD patients, training in reappraisal-by-distancing, in terms of its ability to influence hypothesized neural and behavioral targets and, once that is established, to demonstrate its ability improve clinically relevant outcome measures.",[29],[404,405,354,406,286,407],"BPD","Treatment","Cognitive Reappraisal","Borderline Personality","2025-12-01",{"date":410,"type":39},"2025-12-03",{"date":412,"type":39},"2024-11-15",{"date":414,"type":23},"2027-07-31",{"name":416,"class":46},"Icahn School of Medicine at Mount Sinai",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":47},"100509447","short-integrative-and-neurocognitive-therapy-for-young-adults-with-borderline-personality-disorder-100509447","NCT05913544","Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder","Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder: a Study Model of Impulsivity Management","SINTYA","Inclusion Criteria:\n\n* Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.\n* High BPD severity level: ZAN-BPD (score ≥ 18\u002F36).\n* Understand, write and read French.\n* Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.\n* Have signed the informed consent.\n* For minor patients, have signed the parental consent by at least one holder of parental authority.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.\n* Intelligence quotient \\\u003C 70.\n* Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).\n* Previous or current participation in specific psychotherapy for BPD.\n* Subject deprived of liberty (by judicial or administrative decision) and\u002For protected by law.\n* Inclusion in another study including psychotherapy for the duration of the study.\n* Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.\n* Subject in period of exclusion from another research protocol.","16 Years","25 Years",{"count":428,"type":23},74,[26],"Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).",[29],"2025-11-20",{"date":434,"type":39},"2025-11-24",{"date":436,"type":39},"2023-11-08",{"date":270,"type":23},{"name":439,"class":46},"Centre Hospitalier Universitaire de Nīmes",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":216},"100608126","treatment-of-borderline-personality-disorder-with-rtms-100608126","NCT07197502","Treatment of Borderline Personality Disorder With rTMS","CLINICAL TRIAL: Treatment of Borderline Personality Disorder by Targeting Ventrolateral Prefrontal-amygdala Circuit With Network-based Neuronavigated Transcranial Magnetic Stimulation","ClinicalBPD","* Age of 18-65\n* DSM-5 Diagnosis of BPD based upon a psychiatric evaluation and ZAN-BPD\n* Fluent English speaker\n* Signed informed consent",{"count":449,"type":23},30,[26],"This project studies the effectiveness of brain stimulation on borderline personality disorder (BPD) symptoms. This study is blinded, randomized and will enroll up to 30 participants.\n\nParticipant will be consented for the study remotely via a secure internet platform called Zoom.\n\nParticipants will undergo up to 2 MRI scans, 2 brain wave recording sessions and up to 30 brain stimulation treatments, and complete symptom assessments and cognitive behavioral tasks on a computer. Participation requires minimum of 17 in person visits over the course of 2.5 months.\n\nParticipants are randomly assigned active or sham brain stimulation. Participants who received sham brain stimulation have the option to receive additional 15 active brain stimulation session.",[29,407,453],"BPD - Borderline Personality Disorder",[404,455,302,29],"rTMS","2025-10-27",{"date":458,"type":39},"2025-10-29",{"date":460,"type":39},"2025-03-01",{"date":120,"type":23},{"name":463,"class":46},"University of California, Los Angeles",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":47},"100362079","shame-propensity-in-borderline-personality-disorder-100362079","NCT03994510","SHame prOpensity in bOrderline Personality Disorder","Study of Shame Propensity as a Prognostic Factor of Suicidal Behaviors in Patients With Borderline Personality Disorder","SHOO","Inclusion criteria:\n\n* To be over 18\n* Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-Text Reviewed Axis II Personality Disorders)\n* Having signed the informed consent\n* Able to understand the nature, the purpose and the methodology of the study\n* Able to understand and perform the clinical evaluations\n\nExclusion criteria:\n\n* Deprived of liberty (by judicial or administrative decision)\n* Protected by law (guardianship)\n* Exclusion period in relation to another protocol\n* Not affiliated to a social security scheme",{"count":473,"type":23},688,[26],"Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition.\n\nNegative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years.\n\nThe main objective is to study the propensity to feel shame as a predictor of SA.\n\nThis include:\n\n* Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning.\n* Identify biological markers predicting SA\n* Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA",[29],[478,479,29,480],"Psychiatry","Suicidal Behavior","Follow-Up Study","2025-09-24",{"date":483,"type":39},"2025-09-30",{"date":485,"type":39},"2020-09-18",{"date":487,"type":23},"2031-09",{"name":45,"class":46},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":496,"targetDuration":4,"studyType":24,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100608254","effectiveness-of-autobiographical-rewriting-workshops-on-the-socio-professional-functioning-of-patients-with-borderline-personality-disorder-undergoing-third-wave-cognitive-and-behavioral-therapy-a-randomized-controlled-trial-100608254","NCT07199166","Effectiveness of Autobiographical Rewriting Workshops on the Socio-Professional Functioning of Patients With Borderline Personality Disorder Undergoing Third-Wave Cognitive and Behavioral Therapy: A Randomized Controlled Trial","ICS","Inclusion Criteria:\n\n* Subjects with borderline personality disorder (assessed by SCID-2),\n* Subjects aged between 18 and 45 years (inclusive).\n\nExclusion Criteria:\n\n* Psychotic disorder (assessed by SCID),\n* Subjects deprived of their liberty (by judicial or administrative decision, or involuntary hospitalization),\n* Subjects under legal protection (guardianship, curatorship, or judicial protection),\n* Subjects not affiliated with a social security,\n* Pregnant or breastfeeding women,\n* Inability to understand the nature, purpose, and methodology of the study,\n* Inability to understand, speak, or write French,\n* Failure to provide informed oral consent to participate in the study.",{"count":497,"type":23},140,[26],"This study evaluates the effectiveness of autobiographical rewriting workshops combined with third-wave Cognitive Behavioral Therapy (CBT) in improving social and professional functioning in individuals with Borderline Personality Disorder (BPD). BPD affects approximately 2 to 6% of the general population and is frequently associated with suicidal behaviors, unstable relationships, and low self-esteem. This disorder is often linked to early traumatic experiences that impact autobiographical memory and self-perception. While Dialectical Behavioral Therapy (DBT) is a standard treatment for BPD, it does not fully address all the needs of patients.\n\nThe aim of this study is to determine whether autobiographical rewriting, which allows individuals to restructure and reinterpret their memories in a more resilient way, can improve autobiographical memory, self-esteem, and reduce emotional symptoms. Participants will be randomized into two groups: one group will undergo autobiographical rewriting workshops in addition to third-wave CBT sessions, while the other group will participate in non-specific writing sessions also in addition to third-wave CBT sessions. The study will compare the two groups to evaluate the effectiveness of autobiographical rewriting workshops in enhancing social and professional well-being.\n\nExpected outcomes include improvements in interpersonal relationships, greater professional stability, and a reduction in emotional symptoms assessed immediately post-intervention, then 3 months and 6 months after. This study may offer a complementary therapeutic approach to existing treatments, helping patients manage their symptoms more effectively and improve their quality of life.",[29,30],[33,502,503],"autobiographical rewriting","third wave CBT","2025-09-22",{"date":483,"type":39},{"date":507,"type":23},"2025-10-01",{"date":509,"type":23},"2028-10-01",{"name":45,"class":46},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":518,"maxAge":19,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":47},"100562656","the-effectiveness-of-group-schema-therapy-in-the-treatment-of-borderline-symptoms-in-adolescents-100562656","NCT06606002","The Effectiveness of Group Schema Therapy in the Treatment of Borderline Symptoms in Adolescents","The Effectiveness of Group Schema Therapy Utilizing Video Material in the Treatment of Borderline Symptoms in Adolescents: A Randomized and Controlled Intervention Study","Inclusion Criteria:\n\n* The participant fulfills at least three diagnostic criteria for borderline personality disorder as assessed by means of the SCID-II structured clinical interview\n* The participant and the participant's parent(s) are able to commit to the research protocol for the entire duration of the study\n* The participant is able to participate in a research intervention in Finnish and fill out the study questionnaires in Finnish\n\nExclusion Criteria:\n\n* The participant currently has psychotic symptoms or a serious risk of suicide\n* The participant has been diagnosed with an intellectual disability or an autism spectrum disorder\n* The main clinical diagnosis of the participant is a substance abuse disorder or substance use would endanger commitment to the research intervention\n* The participant has another illness or symptom that endangers the participant's ability to complete the study\n* The participant receives some other treatment specifically aimed at borderline personality disorder symptoms","15 Years",{"count":520,"type":23},64,[26],"The goal of this randomized and controlled trial is to assess the effectiveness of group schema therapy in the treatment of adolescents with borderline symptoms. The intervention utilizes self-recorded video material as an experiential method. The intervention comprises 30 group sessions and 8 individual sessions. Additionally, there are group sessions for the participants' parents. Participants in the control group receive treatment as usual.",[524,29],"Borderline Symptoms",[526,527,528,529],"adolescents","borderline disorder","schema therapy","randomized controlled study","2025-09-04",{"date":532,"type":39},"2025-09-11",{"date":534,"type":39},"2025-08-01",{"date":536,"type":23},"2029-12",{"name":538,"class":539},"Turku University Hospital","OTHER_GOV",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":555,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":47},"100385276","transcranial-direct-current-stimulation-tdcs-neuromodulation-of-executive-function-across-neuropsychiatric-populations-100385276","NCT04296604","Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations","Inclusion Criteria\n\n1. Male and female outpatients 18-65 years of age\n2. A diagnosis of traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorders meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.\n\nExclusion Criteria\n\n1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, shunts, pacemakers, pregnancy.\n2. Active substance dependence (except for tobacco and cannabis).\n3. Pregnant or nursing females.\n4. Inability to participate in testing procedures.\n5. Additional exclusion criteria for healthy controls:\n\n   1. Diagnosis of psychiatric of neurological disorder\n   2. Ongoing treatment with any psychotropic medications.",{"count":547,"type":23},600,[26],"In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.",[551,112,552,553,61,29,554],"Traumatic Brain Injury","Bipolar Disorder","Schizophrenia","Substance Use Disorders",[556,557],"Transcranial Direct Current Stimulation","Executive Function",{"date":559,"type":39},"2025-09-10",{"date":561,"type":39},"2014-09",{"date":563,"type":23},"2026-04",{"name":565,"class":46},"Massachusetts General Hospital",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":573,"targetDuration":4,"studyType":24,"phases":574,"briefSummary":575,"conditions":576,"keywords":577,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":47},"100216660","phase-2-a-novel-drug-for-borderline-personality-disorder-100216660","NCT02097706","A Novel Drug for Borderline Personality Disorder","A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder","Inclusion criteria\n\nParticipants will be eligible to proceed in the study if they meet all of the following criteria (as determined in the screening session):\n\n1. Men and women aged between 18-65 years of age\n2. A current diagnosis of BPD, or a score ≥ 8 on Diagnostic Interview for Borderline patients, or a score ≥ 15 on Zanarini Rating Scale for Borderline Personality Disorder\n3. Proficient in reading and writing English\n\nExclusion criteria\n\nPotential participants who meet the criteria for any of the following will be excluded from participating in the study:\n\n1. Clinical evidence of acute delirium or severe head injury\n2. Epilepsy or other current seizure disorder, history of seizures or convulsions (not including febrile convulsions), or presence of predisposing factors for epilepsy.\n3. Clinically significant hepatic or renal impairment, haematological, or cardiovascular disease.\n4. Concomitant use of NMDA antagonists (amantadine, ketamine, dextromethorphan), L-dopa, dopamine agonists or anticholinergics.\n5. Lifetime diagnosis of schizophrenia, schizoaffective disorder, substance-induced psychotic disorder or bipolar I disorder (DSM-V).\n6. Risk of suicide such that inpatient admission is required, as determined by PI (psychiatrist) on the basis of clinical assessment and baseline BPDSI-IV and\u002For ZAN-BPD suicide subscale scores.\n7. Taking more than 4 psychotropic medications.\n8. Planned changes to psychotropic medication or psychotherapy regime.\n9. Substance abuse or dependence requiring intervention or rehabilitation in last 3 months.\n10. Pregnant or breastfeeding; if of child-bearing age, not using appropriate contraceptive precaution.",{"count":83,"type":23},[85],"Borderline Personality Disorder (BPD) is one of the most prevalent psychiatric disorders with high morbidity and mortality. It affects the lives of millions worldwide and is often highly incapacitating, leading to significant psychosocial dysfunction. Moreover, nearly all patients have experienced suicidal ideation and about 10% actually commit suicide, a rate almost 50 times higher than in the general population. Mostly young women are at greater risk for the disorder and are three times more likely to be diagnosed with BPD than men.\n\nBPD aetiology is complex and could be explained by both biological and environmental factors. Among the environmental factors, sexual or physical abuse, parental divorce, loss or illnesses are identified as the most common ones. These factors can induce dysfunctional behaviours, which might cause emotional dysregulation, high impulsivity and frequent self- injurious behaviour.\n\nHowever, there are no pharmacologic interventions that are known to be specifically effective to treat BPD. Therapeutic options for this devastating disorder is still far from adequate for treating acute illness episodes, relapses, and recurrences and in restoring premorbid functioning. In addition, some patients are unable to tolerate existing therapies for BPD, which leads to either frequent changes in medications or to non-adherence. Therefore there is an urgent need for the development of more rapidly effective treatments for BPD.\n\nA growing body of evidence suggests that glutamatergic neurotransmission, in particular N-methyl-D-aspartate (NMDA) subtype may play a role in the pathophysiology of multiple psychiatric disorders. This has led to various clinical trials with glutamate modulating drugs. The trial drug is an uncompetitive NMDA receptor antagonist approved for Alzheimer's disease is increasingly being studied in a variety of non-dementia psychiatric disorders. Results from these studies have proved that the trial drug was safe and well tolerated and has the potential for use in the treatment of psychiatric disorders.\n\nTo date, there are no published data on the use of trial drug in the treatment for BPD. Therefore, the investigators intend to study the efficacy of this novel drug as an addition to ongoing therapy with atypical antipsychotics in patients with Borderline Personality Disorder. This study will recruit 150 BPD patients. The patients will be randomly allocated to receive either the study medication (20mg\u002F day) or placebo via oral administration for twelve weeks. To observe the efficacy of the trial treatment, all participants will be assessed at various time intervals for different borderline and cognitive symptoms.",[29],[578,579,580],"Boderline Personality Disorder","Mental Illness","Cognition",{"date":582,"type":39},"2025-08-15",{"date":584,"type":4},"2015-01",{"date":586,"type":23},"2025-12",{"name":588,"class":46},"The Alfred",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":595,"targetDuration":597,"studyType":109,"phases":4,"briefSummary":598,"conditions":599,"keywords":606,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":620},"100547361","brief-admission-by-self-referral-for-individuals-with-self-harm-effects-on-compulsory-care-100547361","NCT06406972","Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care","Inclusion Criteria:\n\n* Living in the uptake area of Lund, Linköping, Helsingborg or Norrköping\n* Age 18-65 years at the time of inclusion\n* Admitted to hospital either diagnosed with ICD-10 diagnosis BPD F60.3, or admitted at least twice with Intentional self-harm X60-83 in combination with one of more of the following diagnoses ADHD (F90.0-F90.X), Bipolar disorder type 2, (F31.8W, F318A-F, F31.0, F31.8-9, F31.8W) or Autism, Atypical autism, Aspergers syndrome (F84.0, F84.1, F84.5) or Mild intellectual disability (F70.0-F70.9).\n\nExclusion Criteria:\n\n* not fulfilling inclusion criteria",{"count":596,"type":23},7000,"5 Years","Brief Admission by self-referral (BA) is a standardized treatment model, providing patient-controlled and person-centered care. It was developed to reduce self-harm and compulsory care by promoting autonomy. Randomized clinical trials have not yielded significant between group differences with respect to inpatient care, including compulsory care. The major difficulty in evaluating BA is preventing the control group from cross-contamination, as in the implementation process of BA, all physicians, all inpatient and outpatient staff as well as managers need to be informed and undergo basic education regarding the intervention. As BA addresses a prevalent and frustrating issue in psychiatric health care, there is considerable risk that the approach leaks to the control group, reducing the possibility to detect between-group differences. In the current study this will be addressed through a register-based approach, comparing similar clinics, implementing BA at different timepoints over time. Individuals with traits of borderline personality disorder will be included and comparisons will be made with respect to compulsory care, voluntary inpatient care and mortality.",[600,601,602,603,29,604,605],"Self-injury","Suicide","Suicide, Attempted","Self-harm","Emergency Psychiatric","Hospitalizations Psychiatric",[607,608,609,610],"Brief Admission by self-referral","self-harm","traits of borderline personality disorder","compulsory care","2025-08-10",{"date":613,"type":39},"2025-08-14",{"date":615,"type":39},"2010-09-15",{"date":617,"type":23},"2025-12-31",{"name":619,"class":46},"Region Skane",4,{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":627,"targetDuration":628,"studyType":109,"phases":4,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":47},"100548708","effects-of-psychiatric-admissions-on-self-harm-and-suicide-in-people-with-borderline-personality-disorder-100548708","NCT06424509","Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder","Inclusion Criteria:\n\n* Psychiatric clinic in Sweden authorized to administer compulsory care for adults. Each clinic per specific calendar year will represent one participant, identified by the clinic's name and the respective year (e.g., Umeå2010, Linköping2013, Malmö2022).\n\nExclusion Criteria:\n\n* No authorization to administer compulsory care for adults",{"count":132,"type":23},"1 Year","The current study aims to evaluate the impact of long (\\>5 days) and\u002For compulsory psychiatric inpatient care on subsequent healthcare utilization for self-harm and suicide in people with borderline personality disorder, a condition characterized by frequent self-harm.\n\nThe basis for this study is the diversity of clinical practices across Swedish regions. By categorizing clinics based on their practices with respect to long and\u002For compulsory psychiatric inpatient care, it is possible to explore the impact of these practices on subsequent somatic and psychiatric healthcare, including emergency care due to self-harm as well as on completed suicides.\n\nAll psychiatric clinics across Sweden authorized to administer compulsory care for adults, totalling 78 clinics will be included. Each clinic per specific calendar year will represent one participant, identified by the clinic's name and the respective year (e.g., Umeå2010, Linköping2013, Malmö2022).\n\nData collection will involve the utilization of the national registers to capture outcome measures and account for confounding factors. The participants will be ranked based on a composite variable, which includes the average number of days spent in inpatient compulsory care and other psychiatric inpatient care exceeding 5 days, among individuals diagnosed with BPD. The top quartile of participants will be compared with the bottom quartile.",[29,603,631,601],"Non-suicidal Self-injury","2025-08-06",{"date":66,"type":39},{"date":635,"type":39},"2010-01-01",{"date":637,"type":23},"2027-01-01",{"name":639,"class":46},"Lund University",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":647,"targetDuration":4,"studyType":24,"phases":649,"briefSummary":650,"conditions":651,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":47},"100578952","disorders-of-the-sense-of-self-and-physical-activity-100578952","NCT06817980","Disorders of the Sense of Self and Physical Activity","sensdesoi","Inclusion Criteria:\n\n* Criteria common to all participants:\n* Men or women aged 18 to 60 inclusive\n* Subject affiliated to a health insurance scheme, beneficiary or beneficiary's beneficiary\n* Able to understand the aims and risks of the research, and to give informed consent\n* Visual acuity \\> 0.7 on the Freiburg Vision Test (Bach 1996) due to the use of visual equipment\n* BMI (body mass index) \\\u003C 40 (due to cardiovascular risk).\n\nPatient-specific criteria:\n\n* With schizophrenia: criteria for schizophrenia as defined in the DSMV (American Psychiatric Association, 2015)\n* With borderline personality disorder: criteria for borderline personality disorder as defined in the DSMV (American Psychiatric Association, 2015)\n* With vestibular disorders: peripheral vestibular disorders established after otolaryngological examination\n\nExclusion Criteria:\n\n* Criteria common to all participants:\n* Serious or unstabilized somatic pathology (including cardiovascular)\n* History likely to affect cerebral anatomy or to be linked to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke...)\n* Presence of joint pain, likely to worsen after exercise\n* \\- Substance use disorders (as defined by DSM-IV TR)\n* 3D vision disorders as measured by the Wirt stereotest (depth perception at a disparity of at least 80'' arc)\n* Movement perception disorders (correct movement discrimination in less than 75% of trials (cf. § V-2.2)\n* History of general anaesthesia in the 3 months preceding the study\n* History of neurological disease\n* Impossibility of giving the subject informed information (subject in emergency situation)\n* Pregnancy declared by patient\n* Breast-feeding\n* Subject in exclusion period (determined by a previous or current study)\n* Subject hospitalized\n* Subject under court protection\n\nExclusion criteria specific to control subjects or patients with vestibular syndrome:\n\nHistory of major psychiatric pathology with current psychotropic medication (i.e., antidepressant, thymoregulator, antipsychotic)",{"count":648,"type":23},168,[26],"Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA). Yet patient adherence to PA is low, at least in the case of SZ. the investigators work and the literature lead the investigators to consider that, in addition to motivational aspects, disorders of the bodily sense of self could play a role in this lack of adherence. Simply walking involves visual movements related to the self, which must be distinguished from movements in the environment. This means a distinction between self and not-self. Furthermore, these movements are all the more difficult to distinguish as they may also result from the fact that hidden objects become visible as a result of our own movement. In all sense-of-self disorders can themselves affect physical training, and the investigators will measure them in the first stage. In the second stage, the investigators will apply a standard, risk-free PA protocol by walking (3x3 sessions of 30 min). the investigators will test the impact of physical training on the sense of self under different conditions, with one environment minimizing self-related movement, vs. 2 environments with a variable level of enrichment (i.e. hidden objects inducing more or less self-related movement).\n\nAt the end of the protocol, the investigators will offer participants who wish to take part in an ancillary study, i.e. a walking session with mixed-reality goggles. These will superimpose a luminous flux on the periphery of the visual field. According to results obtained in the laboratory, this flux could restore sensory mechanisms impaired in schizophrenia. the investigators will use these glasses in the most difficult condition for the patient, and verify their impact.",[652,29,653],"SCHIZOPHRENIA 1 (Disorder)","Vestibular Syndromes",{"date":632,"type":39},{"date":238,"type":23},{"date":657,"type":23},"2028-09-01",{"name":659,"class":46},"University Hospital, Strasbourg, France",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":24,"phases":670,"briefSummary":671,"conditions":672,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":72},"100492933","compassion-for-psychiatric-disorders-and-self-stigma-100492933","NCT05698589","COMpassion for Psychiatric Disorders And Self-Stigma","Compassion Focused Therapy (CFT) for the Reduction of the Internalized Stigma of Mental Disorders: a Multi-center, Prospective, Randomized, Controlled Study","COMPASS","Inclusion Criteria:\n\n1. Patient ≥18 years of age\n2. Patient informed of the results of the preliminary medical examination\n3. Patient affiliated to a social health insurance plan (beneficiary or beneficiary's family)\n4. Patient with one or several diagnoses of chronic psychiatric disorder (schizophrenia, schizoaffective disorder, bipolar disorder, recurrent major depression, borderline personality disorder) or a neurodevelopmental disorder (autism spectrum disorder) treated as an outpatient or in a day hospital\n5. CGI-Severity score\\\u003C6 assessed by the psychiatrist (Berk et al., 2008) ISMI score indicating moderate to high self-stigma (\\>2.5; Lysaker et al., 2007)\n\n   Exclusion criteria:\n6. Patient in an exclusion period determined by a previous or ongoing study\n7. Patient participating in an interventional study involving psychotherapy or an experimental drug\n8. Patient in acute episode of their disorder according to the CGI Severity score\n9. Patient in a medical emergency or immediate life-threatening situation\n10. Patients with an intellectual disability (IQ\\\u003C70) estimated via the fNART (Mackinnon \\& Mulligan, 2005)\n\n12\\. Legal issues: care under constraint or patient deprived of freedom because of a judicial measure 13. Patient who does not speak and read French sufficiently",{"count":669,"type":23},336,[26],"People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into society . Stigmatization can also be assimilated by patients themselves - i.e. self-stigma. Self-stigma is involved in diminished coping skills that lead to social avoidance and difficulties in adhering to care . Reducing self-stigma and its emotional corollary, shame, is thus crucial to attenuate the disability associated with mental illness. Shame is inherent to self-stigma and leads to difficulties in adhering to care as well as greater severity of clinical presentations . Compassion Focused Therapy (CFT) is a third wave cognitive behavioral therapy that targets shame reduction and hostile self-to-self relationship and allows for symptom improvement while increasing self-compassion, a major resilience factor . Although shame is a prominent part of the concept of self-stigma, the efficacy of CFT has never been evaluated in individuals with high levels of self-stigma.\n\nIn this study, the investigators will evaluate the efficacy and acceptability of a group based CFT program on decreasing self-stigma, compared to treatment as usual (TAU) and a psychoeducation program whose efficacy has been assessed in a previous trial.",[552,553,137,29,673],"Autism Spectrum Disorder",{"date":632,"type":39},{"date":676,"type":39},"2023-04-03",{"date":678,"type":23},"2028-03-01",{"name":659,"class":46}]